CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
CORCEPT THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
CORCEPT THERAPEUTICS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q2 25 | % of revenue | YoY |
|---|---|---|---|---|
| Hypercortisolism Products | $208.58M | $194.43M | 81.4% | +7.3% |
| Lifyorli | $47.56M | $0 | 18.6% | – |
By region
From the segment and revenue-disaggregation notes of Corcept Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.